Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.

van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF.

Front Immunol. 2018 Dec 18;9:3016. doi: 10.3389/fimmu.2018.03016. eCollection 2018.

2.

Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.

van Balen P, van Luxemburg-Heijs SAP, van de Meent M, van Bergen CAM, Halkes CJM, Jedema I, Falkenburg JHF.

Transplantation. 2017 Dec;101(12):2850-2854. doi: 10.1097/TP.0000000000001713.

PMID:
28252558
3.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

4.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Pont MJ, Hobo W, Honders MW, van Luxemburg-Heijs SA, Kester MG, van Oeveren-Rietdijk AM, Schaap N, de Boer HC, van Bergen CA, Dolstra H, Falkenburg JH, Griffioen M.

Haematologica. 2015 Oct;100(10):e419-22. doi: 10.3324/haematol.2015.125021. Epub 2015 Jun 11. No abstract available.

5.

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH.

Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18.

PMID:
23777765
6.

Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.

Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, van Bergen CA, Marijt EW, Oudshoorn M, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jan;19(1):40-8. doi: 10.1016/j.bbmt.2012.07.020. Epub 2012 Aug 4.

7.

Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.

Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1196-204. doi: 10.3324/haematol.2011.049478. Epub 2012 Mar 14.

8.

Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.

Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, Marijt EW, Kruisselbrink AB, Frederik Falkenburg JH, Heemskerk MH.

Biol Blood Marrow Transplant. 2012 Feb;18(2):210-9. doi: 10.1016/j.bbmt.2011.10.018. Epub 2011 Oct 19.

9.

High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.

Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, Kester MG, Mulder A, Willemze R, Falkenburg JH, Griffioen M.

Cancer Res. 2010 Nov 15;70(22):9073-83. doi: 10.1158/0008-5472.CAN-10-1832. Epub 2010 Nov 9.

10.

HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1-specific CD4+ T cell responses showing immunogenicity of all HLA-DPB1 alleles.

Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1282-92. doi: 10.1016/j.bbmt.2010.03.018. Epub 2010 Mar 27.

11.

Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro.

Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH.

Blood. 2010 Jan 7;115(1):151-3. doi: 10.1182/blood-2009-10-249821. No abstract available.

PMID:
20056799
12.

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Rutten CE, van Luxemburg-Heijs SA, Griffioen M, Marijt EW, Jedema I, Heemskerk MH, Posthuma EF, Willemze R, Falkenburg JH.

Leukemia. 2008 Jul;22(7):1387-94. doi: 10.1038/leu.2008.90. Epub 2008 Apr 17.

PMID:
18418406
13.

Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.

Griffioen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA, von dem Borne PA, van Rood JJ, Willemze R, Falkenburg JH.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42. doi: 10.1073/pnas.0712250105. Epub 2008 Mar 3.

14.

Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing.

de Vries JF, von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Willemze R, Falkenburg JH, Barge RM.

Haematologica. 2007 Dec;92(12):1671-8.

15.

Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.

Hoogendoorn M, Jedema I, Barge RM, van Luxemburg-Heijs SA, Beaumont F, Marijt EW, Willemze R, Falkenburg JH.

Leukemia. 2007 Dec;21(12):2569-74. Epub 2007 Jul 5. No abstract available.

PMID:
17611558
16.

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay.

Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de Meent M, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43.

17.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

PMID:
17234742
18.

Similar potential to become activated and proliferate but differential kinetics and profiles of cytokine production of umbilical cord blood T cells and adult blood naive and memory T cells.

Kloosterboer FM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Hum Immunol. 2006 Nov;67(11):874-83. Epub 2006 Aug 28.

PMID:
17145367
19.

Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.

von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Jedema I, Mulder A, Willemze R, Falkenburg JH.

Leukemia. 2006 Jun;20(6):1040-6.

PMID:
16525495
20.

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer.

Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH.

Blood. 2006 Jun 15;107(12):4954-60. Epub 2006 Feb 23.

PMID:
16497972
21.

Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.

Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, van Egmond HM, Willemze R, Falkenburg JH.

Blood. 2005 Dec 1;106(12):3955-7. Epub 2005 Aug 11.

PMID:
16099884
22.

Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion.

Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, van Egmond HM, Barbui AM, Strijbosch MP, Willemze R, Falkenburg JH.

Leukemia. 2005 Jan;19(1):83-90.

PMID:
15526024
23.

Umbilical cord blood-naive T cells but not adult blood-naive T cells require HLA class II on antigen-presenting cells for allo-immune activation.

Kloosterboer FM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Hum Immunol. 2004 Apr;65(4):328-39.

PMID:
15120187
24.

Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.

Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP, Kester MG, Marijt WA, Goulmy E, Willemze R, Falkenburg JH.

Leukemia. 2004 Apr;18(4):798-808.

PMID:
14973499
25.

The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.

van der Hoorn MA, van Luxemburg-Heijs SA, van Bergen CA, Bongaerts R, Willemze R, Falkenburg JH.

Methods. 2003 Oct;31(2):113-9.

PMID:
12957568
26.

Similar myeloid recovery despite superior overall engraftment in NOD/SCID mice after transplantation of human CD34(+) cells from umbilical cord blood as compared to adult sources.

Noort WA, Wilpshaar J, Hertogh CD, Rad M, Lurvink EG, van Luxemburg-Heijs SA, Zwinderman K, Verwey RA, Willemze R, Falkenburg JH.

Bone Marrow Transplant. 2001 Jul;28(2):163-71.

27.

Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy.

Brouwer RE, Zwinderman KH, Kluin-Nelemans HC, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Exp Hematol. 2000 Feb;28(2):161-8.

PMID:
10706072
28.

Aplastic anaemia in donor cells 14 years after bone-marrow transplant.

Melenhorst JJ, van Luxemburg-Heijs SA, Landegent JE, Willemze R, Fibbe WE, Falkenburg JH.

Lancet. 1999 Jun 12;353(9169):2037-8. No abstract available.

PMID:
10376622
29.

HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells.

Mutis T, Schrama E, van Luxemburg-Heijs SA, Falkenburg JH, Melief CJ, Goulmy E.

Blood. 1997 Aug 1;90(3):1083-90.

PMID:
9242539
33.

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

J Clin Invest. 1995 Aug;96(2):877-83.

34.

Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.

van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM, Brand A.

Blood. 1994 Feb 15;83(4):1060-6.

PMID:
8111046
35.

Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

Falkenburg JH, Faber LM, van den Elshout M, van Luxemburg-Heijs SA, Hooftman-den Otter A, Smit WM, Voogt PJ, Willemze R.

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):305-9.

PMID:
8280712
36.

Separation, enrichment, and characterization of human hematopoietic progenitor cells from umbilical cord blood.

Falkenburg JH, van Luxemburg-Heijs SA, Zijlmans JM, Fibbe WE, Kluin-Nelemans JC, Kanhai HH, Willemze R.

Ann Hematol. 1993 Nov;67(5):231-6.

PMID:
7694664
37.

Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.

Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

J Exp Med. 1992 Nov 1;176(5):1283-9.

38.

Selective outgrowth of CD45RO+ V gamma 9+/V delta 2+ T-cell receptor gamma/delta T cells early after bone marrow transplantation.

van der Harst D, Brand A, van Luxemburg-Heijs SA, Kooij-Winkelaar YM, Zwaan FE, Koning F.

Blood. 1991 Oct 1;78(7):1875-81.

PMID:
1832995
39.

Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Falkenburg JH, Goselink HM, van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, et al.

J Exp Med. 1991 Jul 1;174(1):27-33.

Supplemental Content

Loading ...
Support Center